Ipilimumab-GVAX Combination Safe for Metastatic Castration-Resistant Prostate Cancer

June 2012, Vol 3, No 4

A combination of ipilimumab and the granulocyte-macrophage colonystimulating factor-transduced allogeneic prostate cancer cells vaccine (GVAX) was feasible and tolerable in an openlabel phase 1 study in men with metastatic castration-resistant prostate cancer (van den Eertwegh AJM, et al. Lancet Oncol. 2012;13:509-517). Based on the toxicity profile and clinical activity, the authors recommended further clinical evaluation of ipilimumab and tumor vaccines in combination.

After a GVAX intradermal priming dose, patients received additional doses every 2 weeks for 24 weeks, for a total of 13 injections. They received intravenous infusions of ipilimumab 0.3, 1.0, 3.0, or 5.0 mg/kg every 4 weeks, for a total of 6 infusions, each administered on the same day as a vaccination. The primary end point was the safety of GVAX. No severe immune-related adverse events (AEs) were reported with the lowest 2 doses. The most common AEs were injection-site reactions, fatigue, and pyrexia.

Clinical activity included durable prostate-specific antigen responses, bone scan improvements, and tumor regression.

Related Articles

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: